Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises on Medivir’s new issue
Mandate

Vinge advises on Medivir’s new issue

March 29, 2010

Medivir AB (publ) (NASDAQ OMX Stockholm) is performing a rights issue for approximately SEK 300 million. The new issue is fully covered by subscription undertakings, declarations of intent and underwriting undertakings from, among others, Carnegie and Jefferies acting as Joint Bookrunners.

Vinge is advising Medivir. Vinge’s team consists of Erik Sjöman, Emil Hedberg and Jesper Schönbeck. In addition, Rikard Stenberg, Maria Doeser and Markus Larsson have been involved in the transaction.

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026